2023
DOI: 10.1016/j.drudis.2023.103506
|View full text |Cite
|
Sign up to set email alerts
|

MRI assessment of cerebral perfusion in clinical trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 75 publications
(98 reference statements)
0
4
0
Order By: Relevance
“…In the experiment, all the samples were injected into the tumor-bearing mice, respectively, followed by imaging detection. The clinical value of MRI lies in its ability to deliver detailed soft tissue information, and the contrast agent could further enhance its detection sensitivity [ 42 ]. Herein, the T 2 signal intensity in the tumor areas was significantly decreased after 24 h of IR780@BSA@SPIO injection, compared to the signal before injection and the PBS group, which was markedly distinct from normal tissues, as demonstrated in Figure 4A and Supplementary Figure S8 ; and the fluorescence intensity of the tumor areas increased over time ( Figure 4B and C ), suggesting that the nanosystem was accumulating in the tumor areas.…”
Section: Resultsmentioning
confidence: 99%
“…In the experiment, all the samples were injected into the tumor-bearing mice, respectively, followed by imaging detection. The clinical value of MRI lies in its ability to deliver detailed soft tissue information, and the contrast agent could further enhance its detection sensitivity [ 42 ]. Herein, the T 2 signal intensity in the tumor areas was significantly decreased after 24 h of IR780@BSA@SPIO injection, compared to the signal before injection and the PBS group, which was markedly distinct from normal tissues, as demonstrated in Figure 4A and Supplementary Figure S8 ; and the fluorescence intensity of the tumor areas increased over time ( Figure 4B and C ), suggesting that the nanosystem was accumulating in the tumor areas.…”
Section: Resultsmentioning
confidence: 99%
“…Also, this inventory is aimed uniquely at pipeline selection and does not provide details or guidance for performing ASL processing. However, literature is available for ASL beginners for designing studies, 35 acquisition protocol, 14 quantification, 36 processing, 17 and clinical use 37 . Most of the pipelines, however, handle raw data and provide CBF in different regions of interest, which can be used for statistical analysis.…”
Section: Discussionmentioning
confidence: 99%
“…Hence, ASL‐measured perfusion can serve as an imaging biomarker for longitudinal assessment of blood flow characteristics in normal human developmental process and in disease. Because perfusion abnormalities are associated with pathophysiological processes such as cancer, 6 neurodegenerative diseases, 7 and kidney diseases, 8 ASL‐measured perfusion changes before and after therapy may provide clinically valuable information about disease progression and treatment response 9 …”
Section: Introductionmentioning
confidence: 99%
“…Hence, ASL-measured perfusion can serve as an imaging biomarker for longitudinal assessment of blood flow characteristics in normal human developmental process and in disease. Because perfusion abnormalities are associated with pathophysiological processes such as cancer, 6 neurodegenerative diseases, 7 and kidney diseases, 8 ASL-measured perfusion changes before and after therapy may provide clinically valuable information about disease progression and treatment response. 9 ASL has also demonstrated good accuracy in the brain compared with [ 15 O]H 2 O-PET, considered gold standard for perfusion imaging 10,11 ; however, its application and clinical validation in other anatomical locations are under development.…”
Section: Introductionmentioning
confidence: 99%